Aisling Capital Management LP 13F holdings
Aisling Capital Management LP reported 14 positions with a total reported value of $471.6M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-13. Top holdings by reported value: BBIO BRIDGEBIO PHARMA INC (72.5%), GLUE MONTE ROSA THERAPEUTICS INC (8.0%), SNDX SYNDAX PHARMACEUTICALS INC (6.1%), CMPS COMPASS PATHWAYS PLC (4.3%), BCAX BICARA THERAPEUTICS INC (3.6%). Against 2026-03-31 it opened 1 new position and exited 0. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Aisling Capital Management LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
14 largest of 14 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| BBIO BRIDGEBIO PHARMA INC | 4,589,611 | $341.8M | 72.5% |
| GLUE MONTE ROSA THERAPEUTICS INC | 1,555,664 | $37.6M | 8.0% |
| SNDX SYNDAX PHARMACEUTICALS INC | 1,316,806 | $28.8M | 6.1% |
| CMPS COMPASS PATHWAYS PLC | 1,432,336 | $20.3M | 4.3% |
| BCAX BICARA THERAPEUTICS INC | 568,919 | $16.9M | 3.6% |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 1,018,018 | $7.8M | 1.6% |
| SRRK SCHOLAR ROCK HLDG CORP | 77,031 | $4.2M | 0.9% |
| URGN UROGEN PHARMA LTD | 108,000 | $4.0M | 0.8% |
| BMEA BIOMEA FUSION INC | 2,048,757 | $3.0M | 0.6% |
| ACRS ACLARIS THERAPEUTICS INC | 434,455 | $2.3M | 0.5% |
| EPRX EUPRAXIA PHARMACEUTICALS INC | 325,000 | $2.1M | 0.5% |
| VTVT VTV THERAPEUTICS INC | 50,000 | $1.9M | 0.4% |
| MRKR MARKER THERAPEUTICS INC | 325,370 | $478.3K | 0.1% |
| OKUR ONKURE THERAPEUTICS INC | 88,607 | $404.0K | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| VTVT VTV THERAPEUTICS INC | 50,000 | $1.9M | 0.4% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 0 in all · reported value as of 2026-03-31
No positions were sold out.
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
No position was increased.
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| BBIO BRIDGEBIO PHARMA INC | 5,089,611 | 4,589,611 | -9.8% | $341.8M |
CIK 1766721 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
